Sivia Capital Partners LLC Purchases 1,500 Shares of United Therapeutics Corporation $UTHR

Sivia Capital Partners LLC raised its position in United Therapeutics Corporation (NASDAQ:UTHR) by 247.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 2,105 shares of the biotechnology company’s stock after buying an additional 1,500 shares during the quarter. Sivia Capital Partners LLC’s holdings in United Therapeutics were worth $1,026,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of UTHR. Torren Management LLC acquired a new stake in United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management raised its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC acquired a new stake in United Therapeutics during the 4th quarter worth $31,000. Wilmington Savings Fund Society FSB lifted its holdings in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in United Therapeutics during the fourth quarter worth about $48,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on UTHR. UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $549.47 on Thursday. The firm has a market cap of $23.33 billion, a price-to-earnings ratio of 20.28, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57. The stock’s 50-day moving average is $567.74 and its 200-day moving average is $518.04. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $6.63 earnings per share. On average, equities analysts expect that United Therapeutics Corporation will post 26.92 EPS for the current year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $562.82, for a total value of $4,671,406.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $25,423,705.04. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $547.87, for a total value of $5,478,700.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,341,594.12. This trade represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 605,743 shares of company stock valued at $340,981,769. 8.60% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.